NCT01527565View on ClinicalTrials.gov

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 20, 2003

Primary Completion Date

February 26, 2003

Study Completion Date

February 26, 2003

Conditions
DiabetesHealthy
Interventions
DRUG

biphasic insulin aspart 70

A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days

Trial Locations (1)

9324

Novo Nordisk Investigational Site, Bloemfontein

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY